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ABSTRACT 24 
 25 
Objective: The aim of this study was to evaluate the ability of topical miconazole to 26 
penetrate the nail. Methods: Bovine hoof, a healthy human nail TurChub® zone of 27 
inhibition model, and an infected nail model were used in this study. In the hoof model, 28 
miconazole was applied to hoof slices subsequently placed on a Trichophyton 29 
mentagrophytes seeded agar plate.  In the TurChub® zone of inhibition assay, topical 30 
miconazole (10%) was applied to full thickness human nails, using T. rubrum as the test 31 
organism.  The infected nail model, using ChubTur® test systems, was performed using 32 
full thickness human nails infected with T. rubrum prior to the application of miconazole 33 
(10%). Drug penetration was assessed by zones of inhibition (ZOI) and ATP recovery, 34 
respectively.  Results: In the hoof model, miconazole showed significantly larger ZOI 35 
after 60 minutes of penetration compared to 8% ciclopirox nail lacquer (P < 0.05). 36 
Similar results were achieved with the TurChub® assay comparing topical miconazole to 37 
8% ciclopirox (P ≤ 0.05). The observed ZOI for 10% efinaconazole and the base 38 
formulations containing either 10% miconazole or 10% fluconazole were equivalent to 39 
total kill (ZOI of 3 - 4 cm) of T. rubrum in the TurChub® cells, indicating 40 
high/therapeutic levels of drug permeation. Base formulations with miconazole, 41 
fluconazole, and efinaconazole were all statistically (P < 0.05) superior to 8% ciclopirox. 42 
In the infected nail model, infected nails treated with topical miconazole demonstrated a 43 
significantly (P ≤ 0.05) lower percentage ATP recovery (i.e. less viable organism) when 44 
compared to 8% ciclopirox, indicating greater antifungal efficacy. Conclusion: 45 
 3 
Miconazole is capable of nail penetration when applied topically as either a previously 46 
marketed formulation or in the penetration enhancing formula.     47 
 48 
INTRODUCTION  49 
Onychomycosis, a fungal infection of the nail most commonly caused by the 50 
dermatophytes Trichophyton rubrum, T. mentagrophytes, and Epidermophyton 51 
floccosum [1-3], is a condition that can cause discomfort and lead to permanent 52 
disfigurement. [4] In turn, it can lead to diminished self-esteem and negative effects 53 
on a patient’s quality of life. [5] Onychomycosis is estimated to affect 2% to 13% of 54 
the general population. [6-10] Its high incidence and prevalence makes it an 55 
important public health problem. [11] 56 
 57 
Onychomycosis leads to nail hyperkeratosis and onycholysis of the nail bed [12], 58 
factors that make drug treatment difficult. [13] Nail thickening makes drug 59 
penetration particularly difficult and lifting of the nail plate from the nail bed creates 60 
an air space in which the fungus can proliferate and in which the drug cannot 61 
permeate. [14-15]    62 
 63 
Treatment of onychomycosis is challenging and cure rates are low [16-18], mostly 64 
secondary to poor patient compliance from prolonged treatment regimens, poor 65 
results, and high re-infection rates. [1, 13-14, 19] Oral agents can result in significant 66 
side effects and potential drug interactions [20-21], particularly in patients with 67 
diabetes, the immunocompromised, and the elderly. [20, 22-26] To avoid such issues, 68 
 4 
topical medications were developed; however many of these agents have lacked 69 
efficacy. [1, 21] It is thought that the poor therapeutic results of such agents are a 70 
consequence of formulation development based on skin drug penetration [27], not 71 
taking into account the physical and chemical differences between nail and skin [1, 72 
15, 27-30], and the nail changes secondary to infection. [14, 31] The need to improve 73 
nail drug delivery has led to the discovery of penetration enhancers that could aid in 74 
drug delivery through nail [32-34], thereby improving outcomes in the treatment of 75 
onychomycosis.  76 
 77 
In this study, we demonstrate the ability of miconazole nitrate to penetrate the nail 78 
employing in vitro nail penetration assays.  Initially, we employed the bovine hoof 79 
model, which uses bovine hooves to simulate the human nail.  The hoof model was 80 
chosen for initial compound screening for several reasons:  1) human nails have a 81 
limited availability, 2) human nails have large variability in thickness, and 3) the 82 
bovine hoof has been shown to be similar in structure and permeability to human nail. 83 
[35] Once efficacy in this hoof model was established, the TurChub® zone of 84 
inhibition assay and infected nail models were employed using healthy and infected 85 
human nails, respectively.  In the bovine hoof model, the ability of miconazole nitrate 86 
to penetrate the nail was compared to 8% ciclopirox nail lacquer. In the TurChub® 87 
zone of inhibition and infected nail models, the ability of 10% miconazole nitrate 88 
combined with a penetration enhancer formulation, was compared to 10% 89 
fluconazole, 8% ciclopirox, and 10% efinaconazole.  90 
 91 
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 92 
 93 
 94 
MATERIALS AND METHOD 95 
Test organisms 96 
In the bovine hoof model, T. mentagrophytes ATCC 24953, taken from the culture 97 
collection at the Center for Medical Mycology, Cleveland, OH was used. T. 98 
mentagrophytes was selected as it is one of the major causes of onychomycosis. 99 
Furthermore, T. mentagrophytes produces conidia consistently and reproducibly. To 100 
obtain conidia for use in the penetration assay, subcultures were inoculated onto 101 
potato dextrose agar plates (PDA) and incubated for 5-7 days at 30 C. Next, 5 mL 102 
of normal sterile saline solution (NS, 0.85% sodium chloride) was added to each 103 
plate and the conidia were harvested, washed three times with sterile saline, and then 104 
resuspended in 5 mL of saline. A hemacytometer was used to determine the cell 105 
concentration in diluted suspension. The working suspension of T. mentagrophytes 106 
conidia was standardized to a final concentration of 2-5 x 105 conidia/mL.      107 
 108 
In the TurChub® zone of inhibition and infected nail models, a T. rubrum strain 109 
isolated from a patient suffering from onychomycosis was used to prepare a conidial 110 
suspension. The test isolate was sub-cultured onto Sabouraud dextrose agar (SDA), 111 
and PDA and incubated at 20-25 °C for 7days. The fungal colonies were then covered 112 
with 5 mL of Ringer’s solution and suspensions of conidial and hyphal fragments 113 
were made. The suspension was then filtered through sterile gauze to remove 114 
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mycelium. The density of the suspension was assessed spectrophotometrically at 600 115 
nm, and the spore suspension adjusted to approximately 1 x 107 spores/mL by 116 
diluting with Ringer’s solution. 117 
 118 
Test formulations  119 
Three penetration enhancing formulations were supplied by Humco Pharmaceuticals 120 
(Austin, TX, USA) containing a novel base formulation comprised of: acetylcysteine, 121 
alcohol, camphor, EDTA, eucalyptus oil, hydroxypropylcellulose, hydroxypropyl 122 
starch phosphate, magnesium aluminum silicate, menthol, propylene carbonate, 123 
propylene glycol, purified water, sodium hydroxide, sodium thioglycolate, rtrontium 124 
chloride, tea tree oil, thymol, and urea. One of the formulations was a placebo 125 
comprised of the base formulation only, while the other two formulations contained 126 
either fluconazole at 10% or miconazole at 10%. Miconazole nitrate 2% was also 127 
tested in the bovine hoof model, whereas 8% ciclopirox topical solution and 128 
efinaconazole at 10% were investigated in the TurChub® zone of inhibition and 129 
infected nail models. 130 
 131 
Treatment groups 132 
In the bovine hoof model, treatment groups included miconazole nitrate 2% (applied 133 
for 30 minutes), miconazole nitrate 2% (applied for 60 minutes), 8% ciclopirox nail 134 
lacquer, and untreated control. 135 
In the TurChub® zone of inhibition and infected nail models, treatment groups 136 
included infected control (agar inoculated with organism but not dosed with test 137 
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sample), non-infected control (control not inoculated with test organism or dosed with 138 
test sample), base formulation with no drug, base formulation with 10% miconazole, 139 
and base formulation with 10% fluconazole, 10% efinaconazole, or 8% ciclopirox 140 
solution.  141 
 142 
Bovine hoof model 143 
Due to the limited availability of human nails and the large variability in their 144 
thickness, a nail penetration model using a bovine hoof was developed as bovine 145 
hooves are comparable in structure and permeability to human nail. Hooves were 146 
obtained from Mahan Packing Co. (Bristolville, OH). After the flesh was removed, 147 
the hooves were cleaned with antibacterial soap and washed with water to remove the 148 
soap. Cleaned hooves were subsequently sliced using a band saw. The thickness of 149 
each slice was measured with an electronic digital caliper and slices 0.5-1.0 mm thick 150 
(mimicking human nails thickness) were autoclaved. Prior to the application of test 151 
formulation, autoclaved slices were soaked in sterile water for 2 hours to prevent 152 
cracking when discs were cut. Three hundred microliters of the test formulation was 153 
applied to the top of the hoof slice and allowed to penetrate for 30 or 60 minutes. 154 
Subsequently, excess formulation was removed and 3 discs cut using an 8 mm biopsy 155 
punch. The discs were then placed, surface up, on a 4 mm thick PDA plate seeded 156 
with T. mentagrophytes ATCC 24953 (2-5 x 105 conidia/mL). The plates were 157 
incubated at 35 °C for 4 days at which time the diameter of the zone of inhibition 158 
(ZOI) was measured and the effective zone calculated. The effective ZOI is defined 159 
as the zone diameter minus the diameter of the disk. 160 
 8 
 161 
TurChub® zone of inhibition 162 
The TurChub® ZOI assay uses a modified Franz cell, in which sections of human 163 
nail serve as the barrier through which the drug initially penetrates prior to reaching 164 
an agar-filled receptor chamber where the dermatophytes grow. 165 
Distal nail clippings were obtained from volunteers’ toenails which had been grown 166 
to a minimum length of 3 mm. Prior to acceptance of the nails, all nail donors were 167 
required to have not used nail varnish or polish on their toenails within 6 months and 168 
to have no visible signs of damage or disease to their nails. Using scissors, nail 169 
clippings were cut into pieces, which were a minimum of 3 mm x 3 mm. The nail 170 
clippings were initially placed in water and heated to 60 °C for 15 min followed by 171 
immersing in a 70% ethanol in water solution and vortex mixed for one minute at 172 
ambient room temperature to disinfect the nails. This process of washing and mixing 173 
by vortex was repeated once. The ethanol solution was then decanted and replaced 174 
with sterile Ringer’s solution, vortex mixed for 1 min, and decanted. This process of 175 
washing with Ringer’s solution was carried out a total of three times. Once the 176 
washing process was complete, the nail clippings were placed into a sterile Petri dish 177 
without a lid and air dried for 30 min at room temperature in a laminar flow cabinet. 178 
The thickness of all the nail sections was measured using a caliper.  179 
 180 
Preparation of the TurChub® cells was performed as described in Traynor et al. [32] 181 
Briefly, the receiver compartment of each TurChub® was filled with agar (PDA) 182 
ensuring complete contact with the agar in the receiver compartment and the 183 
 9 
underside of the nail. The T. rubrum organism suspension was pipetted onto the agar 184 
surface within individual TurChub® cells and then left to dry. The surface of the nail 185 
mounted in the gasket section of a TurChub® cell was dosed with 100 μL of test 186 
sample and the TurChub® cell was occluded and incubated at 20-25 °C for a total of 187 
14 days. Infected and non-infected controls were also included.  188 
 189 
Infected nail model 190 
The onychomycosis nail model uses infected human nail mounted in the gasket 191 
section of a modified Franz cell (ChubTur® cells). In the onychomycosis model, 192 
distal nail clippings infected with T. rubrum were mounted into the validated 193 
ChubTur® gasket system. The receiver compartment of each ChubTur® was then 194 
partially filled with an inert sterile humidity control medium (Ringer’s solution). The 195 
cells were then incubated at 20-25 °C for 14 days to allow full growth of the 196 
organism on the nail. After establishing the growth of the organism on the nails, the 197 
nails were dosed daily for 7 days with 2 μL of the test formulations. Additional 198 
samples were also set up as an infected control to monitor the growth of T. rubrum on 199 
the nail samples over the incubation period, and control nails without any infection 200 
were also set up and incubated to ensure the absence of contamination. The 201 
effectiveness of each formulation was determined after removing the nail sample 202 
from the cell (24 h after the final dose). The presence of viable microorganisms was 203 
measured by a validated bioluminescence ATP method, in which the amount of 204 
luminescence measured from the infected nails is directly proportional to the amount 205 
of ATP concentration. In turn, the level of ATP detected is an indication of the 206 
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viability of T. rubrum in the onychomycosis nail. 207 
 208 
To ensure the test formulations were compatible with the ATP assay; the direct effect 209 
of the formulations on the ATP assay itself was investigated independently of the 210 
nails and organisms. There was no substantial interference with any of the 211 
formulations with the ATP assay, in which the percentage recovery was within ± 10% 212 
of the ATP standard. Therefore, the ATP assay was found to be ‘fit for purpose’ for 213 
the quantification of samples in the infected nail investigation. 214 
 215 
Statistical Analysis 216 
For analyses, the mean effective ZOI ± the standard deviation was calculated from the 217 
obtained data and compared between different treatment groups. The one-way 218 
ANOVA with a Bonferroni post-hoc test was employed in determining significance. 219 
All statistical analyses were performed using Statistical Package for Social Science 220 
(SPSS) for Windows, version 16.0 (Chicago, IL). A P-value of ≤ 0.05 was considered 221 
statistically significant. 222 
The statistical analysis of the infected nail investigation was performed for all 223 
test formulations as a complete population using SPSS for Windows, version 19.0 224 
(Chicago, IL). Statistical comparison was performed using a one-way ANOVA 225 
with a Tukey’s post-hoc test, where a P-value of ≤ 0.05 was considered statistically 226 
significant (95% confidence level). 227 
 228 
RESULTS 229 
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Table 1 and Figure 1 show the average effective ZOI for each treatment group in the 230 
bovine hoof model. As expected, the untreated controls showed no ZOI (average zone 231 
size of 0.0 mm). Miconazole nitrate 2%, 30 and 60 minute exposure, demonstrated 232 
significant activity when compared to the untreated control (P < 0.05) indicating that 233 
miconazole nitrate was able to penetrate the hoof material and cause inhibition of T. 234 
mentagrophytes. Importantly, miconazole nitrate 2%, following 60 minutes exposure, 235 
showed significantly larger ZOI when compared to 8% ciclopirox nail lacquer (P < 236 
0.05). Miconazole nitrate 2%, following 30 minutes exposure, showed a trend 237 
towards increased ZOI, as compared to 8% ciclopirox nail lacquer (P = 0.07) albeit 238 
not statistically significant. Miconazole nitrate showed significantly larger zone sizes 239 
when left for 60 minutes, as compared to 30 minutes (P < 0.05).  240 
 241 
In the TurChub® ZOI model, following application of a single dose (100 μL) of the 242 
base penetration enhancer formulations containing 10% miconazole and 10% 243 
fluconazole for 14 days, the mean ZOI of T. rubrum observed were 3.57 ± 0.30 and 244 
3.48 ± 0.15 cm, respectively (Figure 2). The mean ZOI for the cells dosed with 100 245 
μL of 10% efinaconazole was 3.58 ± 0.20. There were no ZOI present after dosing of 246 
the nails with the 100 μL of the placebo base penetration enhancer formulation or 8% 247 
ciclopirox. The observed ZOI for the 10% efinaconazole and the base penetration 248 
enhancer formulations containing either 10% miconazole or 10% fluconazole were 249 
equivalent to total kill (ZOI of 3 - 4 cm) of T. rubrum in the TurChub® cells, which is 250 
indicative of potency and high/therapeutic levels of drug permeating through the nail. 251 
The base formulations with 10% miconazole and 10% fluconazole, and the marketed 252 
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product with 10% efinaconazole, were all statistically (P < 0.05) superior to 8% 253 
ciclopirox.  254 
 255 
Following the infected nail investigation whereby the nails were treated daily for 7 256 
days with 2 µL of the test formulations (Figure 3), the greatest decrease in percentage 257 
ATP recovery compared to the infected control was observed for the 10% 258 
efinaconazole solution (3.33%) and the base penetration enhancing formulations with 259 
10% w/w miconazole (4.75%) and 10% w/w fluconazole (6.57%). The 260 
aforementioned ATP levels, which were all statistically similar (P > 0.05), could be 261 
considered baseline, and therefore equivalent to total kill of the organism. The ATP 262 
following treatment with 8% ciclopirox was 20.02% compared to the infected control, 263 
indicating this test formulation was significantly less efficacious than the base 264 
penetration enhancing formulation with 10% w/w miconazole and the 10% 265 
efinaconazole solution (P ≤ 0.05). Moderate anti-fungal efficacy was observed from 266 
the placebo base penetration enhancing formulation (79.96% ATP recovery compared 267 
to the infected control); however, this was significantly less than all of the active test 268 
formulations (P ≤ 0.05). 269 
 270 
Discussion 271 
The data showed that miconazole with and without penetration enhancer can 272 
penetrate the nail as demonstrated using several nail models. In the infected nail 273 
model, the data showed the greatest reduction in ATP recovery (indicating potent 274 
antifungal activity) compared to the infected control, following treatment with  the 275 
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efinaconazole solution and miconazole or fluconazole in the penetration enhancing 276 
formulation (3.33%, 4.75% and 6.57% ATP recovery, respectively). There was no 277 
statistical difference between the percentage ATP recovery for the three 278 
aforementioned formulations (P > 0.05), and the results reflect those observed in the 279 
TurChub® investigation where there was complete kill of T. rubrum in the test 280 
systems following treatment with the same three formulations. The highest 281 
percentage ATP recovery (indicating least antifungal activity) compared to the 282 
infected control was observed following treatment with 8% ciclopirox (20.02% ATP 283 
recovery). A significantly (P ≤ 0.05) higher percentage ATP recovery was observed 284 
after the application of 8% ciclopirox compared to the base formulation with 285 
miconazole and the base formulation with efinaconazole; however, there was no 286 
statistical difference between the 8% ciclopirox and the base formulation with 287 
fluconazole (P > 0.05). These results indicate that miconazole and efinaconazole were 288 
statistically superior than 8% ciclopirox in the treatment of T. rubrum infected full 289 
thickness nails, whereas no statistical differentiation was seen between fluconazole 290 
and 8% ciclopirox. Moderate antifungal efficacy was observed from the vehicle base 291 
formulation (79.96% ATP recovery), which was significantly less than that of each of 292 
the active formulations [P≤ 0.05]. 293 
 294 
Previously published data supports our findings.  In a Franz cell diffusion ZOI assay 295 
which was similar to our TurChub® zone of inhibition assay, 5% efinaconazole 296 
demonstrated average zone sizes ± SD of 2.52 ± 0.42. [36], while ciclopirox 297 
demonstrated no zones of inhibition.  These findings support our data in which 10% 298 
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efinaconazole showed mean zone sizes ± SD of 10% was 3.58 ± 0.20, and ciclopirox 299 
8% showed no zones of inhibition.  300 
 301 
CONCLUSION  302 
In the hoof model assay, it was shown that miconazole can penetrate hoof material 303 
and exhibit antifungal activity. The findings of the hoof model were then further 304 
explored using human nail models, which are more clinically relevant.  Data from the 305 
TurChub® ZOI and infected nail models showed the ability of miconazole nitrate to 306 
penetrate human nail and inhibit fungal growth as measured by ZOI and ATP 307 
recovery, respectively. The data indicates that 10% miconazole nitrate in the 308 
penetration enhancing formulation is equivalent to 10% efinaconazole and superior to 309 
8% ciclopirox, suggesting that miconazole nitrate may be effective in the topical 310 
treatment of onychomycosis.  311 
 312 
 313 
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Table 1. Bovine hoof model effective zones of inhibition 480 
 481 
 Average Effective Zone 
of Inhibition ± SD  
(mm) 
P-values against 
Untreated Control 
Miconazole Nitrate 2%  
(60 minutes) 
26.5 ± 9.7  < 0.0001 
Miconazole Nitrate 2%  
(30 minutes) 
12.7 ± 8.1  0.0010 
8% Ciclopirox Nail Lacquer 2.8 ± 3.4  1.0000 
Untreated Control 0.0 ± 0.0  ----- 
 482 
 483 
 484 
 485 
 486 
 487 
 488 
Figure 1.  The effective zone in the bovine hoof model was assessed by subtracting the 8 489 
mm diameter of the bovine hoof disc from the zone of inhibition diameter (arrow). 490 
 491 
Figure 2. Mean ZOI of T. rubrum on PDA in TurChub® cells that were mounted with 492 
distal nail clippings and treated with a single 100 μL dose of test formulation. The cells 493 
were incubated at 20-25 °C for 7 days after inoculation with T. rubrum (mean ± SD, n=6 494 
 22 
active, n=3 placebo). 495 
 496 
 497 
Figure 3.  The amount of ATP recovered from the nail 24 h after the final treatment, 498 
presented as a percentage of the T. rubrum infected control, following daily treatment (2 499 
μL) for 7 days using the base penetration enhancing formulations (with 10% w/w 500 
miconazole, 10% fluconazole and the placebo), the 10% efinaconazole solution and the 501 
8% ciclopirox topical nail lacquer (mean ± SD, n=6 active, n=3 placebo/control). 502 
